Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)
CM Ballantyne, R Weiss, T Moccetti, A Vogt… - The American journal of …, 2007 - Elsevier
Patients at risk of coronary heart disease may not achieve recommended low-density
lipoprotein (LDL) cholesterol goals on statin monotherapy. This study was designed to …
lipoprotein (LDL) cholesterol goals on statin monotherapy. This study was designed to …
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study)
HE Bays, MH Davidson, R Massaad, D Flaim… - The American journal of …, 2011 - Elsevier
The present multicenter, 6-week, randomized, double-blind, parallel-group, clinical trial
evaluated the safety and efficacy of ezetimibe (10 mg) added to stable rosuvastatin therapy …
evaluated the safety and efficacy of ezetimibe (10 mg) added to stable rosuvastatin therapy …
Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk
YJ Yang, SH Lee, BS Kim, YK Cho, HJ Cho… - Clinical …, 2017 - Elsevier
Purpose The aim of this study was to evaluate the efficacy and tolerability of
rosuvastatin/ezetimibe combination therapy in Korean patients with high cardiovascular risk …
rosuvastatin/ezetimibe combination therapy in Korean patients with high cardiovascular risk …
Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial
GG Schwartz, MA Bolognese, BP Tremblay… - American Heart …, 2004 - Elsevier
BACKGROUND: This double-blind, multicenter, randomized trial compared rosuvastatin and
atorvastatin for reducing low-density lipoprotein cholesterol (LDL-C) in adults with …
atorvastatin for reducing low-density lipoprotein cholesterol (LDL-C) in adults with …
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
AG Olsson, H Istad, O Luurila, L Ose, S Stender… - American Heart …, 2002 - Elsevier
Background Despite the demonstrated benefits of low-density lipoprotein cholesterol (LDL-
C) reduction in reducing the risk of coronary heart disease, many patients receiving lipid …
C) reduction in reducing the risk of coronary heart disease, many patients receiving lipid …
Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a …
R Paoletti, M Fahmy, G Mahla… - Journal of …, 2001 - journals.sagepub.com
Background Rosuvastatin (Crestor), a new, highly efficacious statin, has demonstrated dose-
dependent low-density lipoprotein cholesterol (LDL-C) reductions of up to 65% in a dose …
dependent low-density lipoprotein cholesterol (LDL-C) reductions of up to 65% in a dose …
Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia
HE Bays, M Averna, C Majul, D Muller-Wieland… - The American journal of …, 2013 - Elsevier
Hypercholesterolemic patients (n= 1,547) at high atherosclerotic cardiovascular disease risk
with low-density lipoprotein cholesterol (LDL-C) levels≥ 100 and≤ 160 mg/dl while treated …
with low-density lipoprotein cholesterol (LDL-C) levels≥ 100 and≤ 160 mg/dl while treated …
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)
PH Jones, MH Davidson, EA Stein, HE Bays… - The American journal of …, 2003 - Elsevier
The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter
trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose …
trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose …
Rosuvastatin/ezetimibe: a review in hypercholesterolemia
YN Lamb - American journal of cardiovascular drugs, 2020 - Springer
Rosuvastatin/ezetimibe combines two lipid-lowering agents: rosuvastatin, an HMG-CoA
reductase inhibitor (ie statin) with particularly strong inhibitory effects on hepatic cholesterol …
reductase inhibitor (ie statin) with particularly strong inhibitory effects on hepatic cholesterol …
Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study
LA Leiter, RS Rosenson, E Stein, JPD Reckless… - Atherosclerosis, 2007 - Elsevier
POLARIS investigated the efficacy and safety of rosuvastatin 40mg and atorvastatin 80mg in
high-risk patients with hypercholesterolemia. Patients (n= 871) were randomized to …
high-risk patients with hypercholesterolemia. Patients (n= 871) were randomized to …